Clinical study of different chemotherapies combined with stereotactic body radiation therapy treating advanced pancreatic cancer in elderly patients
Zheng Wei
Kang Jingbo
Wen Juyi
Zhang Xinhong
Abstract：Objective To analyze effectiveness and safety of CyberKnife stereotactic body radiation therapy (SBRT) combined with gemcitabine or tegafur/gimeracil/oteracil potassium(TS-1) chemotherapy in the treatment of advanced pancreatic cancer in elderly patients.Methods Totally 60 patients aged 65-79 years with locally advanced or metastatic pancreatic cancer from August 2013 to August 2015 in Navy General Hospital were enrolled.All patients bad CyberKnife SBRT(5-8 Gy/f,25-40 Gy/5f,5 f/week) due to primary tumor and metastatic retroperitoneal lymph nodes and were divided into 2 groups by different chemotherapy plans:G group(gemcitabine,1 g/time,1 time/d,d1,d8) and S group(TS-1,40 mg/time,2 times/d,d1-14),with 30 cases in each group.Senquential chemotherapies were carried out for at least 4 cycles 3 weeks after radiotherapy.Effective rate,adverse reactions,overall survival(OS) and progression free survival(PFS) were analyzed through follow-up.Results Three months after radiotherapy,effective rates in G group and S group were 80.0％ (24/30) and 76.7％ (23/30) respectively;after sequential chemotherapy,effective rates in G group and S group were 63.3％ (19/30) and 60.0％ (18/30) respectively;differences of effective rates were not significant between groups (P =0.754,P =0.791).The incidence of adverse reactions had no significant difference between groups (P ＞ 0.05).Median OS in G group and S group were 10.0 and 11.5 months;OS rates of 0.5 year,1 year,2 years were 93.3％ (28/30),40.0％ (12/30),10.0％ (3/30) and 86.7％ (26/30),46.7％ (14/30),13.3％ (4/30),respectively;median PFS were 10.0 and 9.0 months;PFS rates of 0.5 year,1 year,2 years were 76.7％ (23/30),20.0％ (6/30),3.3％ (1/30) and 80.0％ (24/30),23.3％ (7/30),3.3％ (1/30),respectively;differences of OS and PFS were not significant between groups (P =0.977,P =0.946).Conclusion CyberKnife SBRT combined with gemcitabine or TS-1 chemotherapy is safe and effective for locally advanced and metastatic pancreatic cancer in elderly patients.
Keywords：Pancreatic cancerStereotactic body radiation therapyCyberKnifeGemcitabine
Publication Date：2016-11-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1657-1661 )